McMillan C, Corner A, Wijesundara D, Choo J, Pittayakhajonwut D, Poredi I
Heliyon. 2025; 11(4):e42533.
PMID: 40034315
PMC: 11872540.
DOI: 10.1016/j.heliyon.2025.e42533.
Bergna A, Lai A, Sagradi F, Menzo S, Mancini N, Bruzzone B
J Med Virol. 2025; 97(2):e70215.
PMID: 39936851
PMC: 11816846.
DOI: 10.1002/jmv.70215.
Parajuli P, Phipps L, Sabo R, Alsaadawi R, Robinson A, French E
J Clin Transl Sci. 2025; 9(1):e22.
PMID: 39911936
PMC: 11795861.
DOI: 10.1017/cts.2024.1166.
Raharinirina N, Gubela N, Bornigen D, Smith M, Oh D, Budt M
Nature. 2025; 639(8053):196-204.
PMID: 39880955
PMC: 11882442.
DOI: 10.1038/s41586-024-08477-8.
Cavalli M, Campoli G, Anselmo A, Brandi R, Fortunato A, Di Spirito M
Sci Rep. 2025; 15(1):3372.
PMID: 39870695
PMC: 11772649.
DOI: 10.1038/s41598-024-84952-6.
SARS-CoV-2 Nsp6-Omicron causes less damage to the Drosophila heart and mouse cardiomyocytes than ancestral Nsp6.
Zhu J, Lee J, Wang G, Duan J, van de Leemput J, Lee H
Commun Biol. 2024; 7(1):1609.
PMID: 39627475
PMC: 11615247.
DOI: 10.1038/s42003-024-07307-x.
A tri-light warning system for hospitalized COVID-19 patients: Credibility-based risk stratification for future pandemic preparedness.
Xu C, Xu Q, Liu L, Zhou M, Xing Z, Zhou Z
Eur J Radiol Open. 2024; 13:100603.
PMID: 39469109
PMC: 11513506.
DOI: 10.1016/j.ejro.2024.100603.
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
Garcia-Perez J, Borobia A, Perez-Olmeda M, Portoles A, Castano L, Campins-Arti M
iScience. 2024; 27(9):110728.
PMID: 39286494
PMC: 11404211.
DOI: 10.1016/j.isci.2024.110728.
The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants.
Lu C, Lung J, Shu L, Liu H, Wu Y, Lin Y
Int J Mol Sci. 2024; 25(17).
PMID: 39273444
PMC: 11394907.
DOI: 10.3390/ijms25179498.
Development and evaluation of vaccination strategies for addressing the continuous evolution SARS-CoV-2 based on recombinant trimeric protein technology: Potential for cross-neutralizing activity and broad coronavirus response.
Du P, Li N, Tang S, Zhou Z, Liu Z, Wang T
Heliyon. 2024; 10(14):e34492.
PMID: 39148990
PMC: 11324815.
DOI: 10.1016/j.heliyon.2024.e34492.
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity.
Tobias J, Steinberger P, Wilkinson J, Klais G, Kundi M, Wiedermann U
Vaccines (Basel). 2024; 12(7).
PMID: 39066432
PMC: 11281395.
DOI: 10.3390/vaccines12070795.
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party....
Spanjaart A, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrian N, Barba P
Leukemia. 2024; 38(9):1985-1991.
PMID: 39043963
PMC: 11347385.
DOI: 10.1038/s41375-024-02336-1.
Household transmission of Omicron variant of SARS-CoV-2 under conditions of hybrid immunity-a prospective study in Germany.
Klee B, Diexer S, Xu C, Gottschick C, Hartmann C, Meyer-Schlinkmann K
Infection. 2024; 53(1):221-230.
PMID: 39037678
PMC: 11825627.
DOI: 10.1007/s15010-024-02352-4.
Detection of SARS-CoV-2-Specific Secretory IgA and Neutralizing Antibodies in the Nasal Secretions of Exposed Seronegative Individuals.
Chwa J, Kim M, Lee Y, Cheng W, Shin Y, Jumarang J
Viruses. 2024; 16(6).
PMID: 38932145
PMC: 11209246.
DOI: 10.3390/v16060852.
Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2-Dominant Period, Japan.
Ogata T, Tanaka H, Kon A, Sakaibori N, Tanaka E
Emerg Infect Dis. 2024; 30(7):1430-1433.
PMID: 38916601
PMC: 11210665.
DOI: 10.3201/eid3007.230968.
The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.
Liao Y, Su J, Zhao J, Qin Z, Zhang Z, Gao W
Front Immunol. 2024; 15:1359380.
PMID: 38881892
PMC: 11176464.
DOI: 10.3389/fimmu.2024.1359380.
How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022.
Althaus T, Overton C, Devaux I, House T, Lapouze A, Troel A
BMC Med. 2024; 22(1):227.
PMID: 38840159
PMC: 11155114.
DOI: 10.1186/s12916-024-03444-6.
Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
Fisman D, Amoako A, Simmons A, Tuite A
PLoS One. 2024; 19(4):e0297093.
PMID: 38574059
PMC: 10994315.
DOI: 10.1371/journal.pone.0297093.
Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
Machado R, Candido E, Aguiar A, Chalup V, Sanches P, Dorlass E
Vaccines (Basel). 2024; 12(2).
PMID: 38400128
PMC: 10892985.
DOI: 10.3390/vaccines12020144.
Assessing the effects of SARS-CoV-2 vaccination on the risk of household transmission during delta variant circulation: a population-based data linkage cohort study.
Vogt F, Rebuli N, Cretikos M, Liu B, Macartney K, Kaldor J
Lancet Reg Health West Pac. 2024; 42:100930.
PMID: 38357393
PMC: 10865045.
DOI: 10.1016/j.lanwpc.2023.100930.